MA34461B1 - BETA-AMYLOID N3PGIU ANTI-PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
BETA-AMYLOID N3PGIU ANTI-PEPTIDE ANTIBODIES AND USES THEREOFInfo
- Publication number
- MA34461B1 MA34461B1 MA35653A MA35653A MA34461B1 MA 34461 B1 MA34461 B1 MA 34461B1 MA 35653 A MA35653 A MA 35653A MA 35653 A MA35653 A MA 35653A MA 34461 B1 MA34461 B1 MA 34461B1
- Authority
- MA
- Morocco
- Prior art keywords
- n3pgiu
- amyloid
- beta
- peptide antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
CETTE INVENTION CONCERNE DES ANTICORPS ANTI-ßA N3PGLU OU UN FRAGMENT SE LIANT À L'ANTIGÈNE DE CEUX-CI. DE PLUS, CETTE INVENTION CONCERNE L'UTILISATION DESDITS ANTICORPS ANTI-ßA N3PGLU OU DUDIT FRAGMENT SE LIANT À L'ANTIGÈNE DE CEUX-CI POUR TRAITER LA MALADIE D'ALZHEIMER.THIS INVENTION INVOLVES ANTI-βA N3PGLU ANTIBODIES OR A FRAGMENT BINDING TO THE ANTIGEN THEREOF. MOREOVER, THIS INVENTION CONCERNS THE USE OF SAID ANTI-βA N3PGLU ANTIBODIES OR ANTIGEN BINDING FRAGMENT THEREOF FOR TREATING ALZHEIMER'S DISEASE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37302610P | 2010-08-12 | 2010-08-12 | |
| PCT/US2011/046994 WO2012021469A1 (en) | 2010-08-12 | 2011-08-09 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34461B1 true MA34461B1 (en) | 2013-08-01 |
Family
ID=44543826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35653A MA34461B1 (en) | 2010-08-12 | 2011-08-09 | BETA-AMYLOID N3PGIU ANTI-PEPTIDE ANTIBODIES AND USES THEREOF |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8679498B2 (en) |
| EP (3) | EP2603523B1 (en) |
| JP (2) | JP5980207B2 (en) |
| KR (1) | KR101498833B1 (en) |
| CN (2) | CN105111308B (en) |
| AU (1) | AU2011289629B2 (en) |
| BR (1) | BR112013004056B8 (en) |
| CA (1) | CA2805114C (en) |
| CL (1) | CL2013000390A1 (en) |
| CO (1) | CO6670526A2 (en) |
| CR (1) | CR20130016A (en) |
| CY (2) | CY1120144T1 (en) |
| DK (3) | DK3339323T3 (en) |
| DO (1) | DOP2013000029A (en) |
| EA (1) | EA023021B1 (en) |
| EC (1) | ECSP13012436A (en) |
| ES (3) | ES2564252T3 (en) |
| GT (1) | GT201300036A (en) |
| HK (1) | HK1180703A1 (en) |
| HR (3) | HRP20160151T1 (en) |
| HU (2) | HUE037524T2 (en) |
| IL (2) | IL224030B (en) |
| LT (2) | LT3042917T (en) |
| MA (1) | MA34461B1 (en) |
| ME (3) | ME03032B (en) |
| MX (2) | MX342782B (en) |
| MY (2) | MY163521A (en) |
| NO (1) | NO3042917T3 (en) |
| NZ (2) | NZ606095A (en) |
| PE (1) | PE20130817A1 (en) |
| PL (3) | PL3042917T3 (en) |
| PT (2) | PT3042917T (en) |
| RS (3) | RS59652B1 (en) |
| SG (2) | SG187586A1 (en) |
| SI (3) | SI3042917T1 (en) |
| UA (1) | UA107600C2 (en) |
| WO (1) | WO2012021469A1 (en) |
| ZA (1) | ZA201300437B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
| PL3042917T3 (en) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| CA2938129A1 (en) * | 2014-02-03 | 2015-08-06 | Cangene Corporation | Humanized beta-amyloid binding molecules and uses thereof |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| EP3693389A1 (en) * | 2014-07-10 | 2020-08-12 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
| TWI599358B (en) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | Combination therapy |
| MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
| EP3234611A1 (en) | 2014-12-19 | 2017-10-25 | Probiodrug AG | Novel method for the detection of pglu-abeta peptides |
| JO3627B1 (en) | 2015-04-30 | 2020-08-27 | H Lundbeck As | Imidazopyrazinones as PDE1 inhibitors |
| CN106699888B (en) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | PD-1 antibody and preparation method and application thereof |
| LT3353212T (en) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
| US10889643B2 (en) | 2016-01-11 | 2021-01-12 | Universität Zürich | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
| JOP20170004B1 (en) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | ANTl-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| TW201740944A (en) * | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | Combination therapy |
| TW201740954A (en) * | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | Combination therapy |
| TWI798751B (en) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| WO2018034977A1 (en) | 2016-08-18 | 2018-02-22 | Eli Lilly And Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| AR110470A1 (en) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | COMBINATION THERAPY TO TREAT ALZHEIMER'S DISEASE |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| KR20190075068A (en) | 2016-10-28 | 2019-06-28 | 하. 룬드벡 아크티에셀스카브 | Combination therapy comprising imidazopyrazinone for the treatment of mental and / or cognitive disorders |
| TW201827467A (en) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | Antibodies to pyroglutamate amyloid-[beta] and uses thereof |
| JOP20190247A1 (en) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| IL272773B2 (en) | 2017-08-22 | 2024-06-01 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CN111465410B (en) | 2017-12-14 | 2022-10-25 | H.隆德贝克有限公司 | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine |
| AR113926A1 (en) | 2017-12-14 | 2020-07-01 | H Lundbeck As | DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| SG11202110504XA (en) * | 2019-03-26 | 2021-10-28 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| JP2022552323A (en) | 2019-10-15 | 2022-12-15 | イーライ リリー アンド カンパニー | Recombinantly engineered lipase/esterase deficient mammalian cell lines |
| WO2021257808A2 (en) * | 2020-06-17 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| IL300059A (en) | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-abeta antibodies |
| AU2021355521A1 (en) * | 2020-10-02 | 2023-05-11 | Eli Lilly And Company | Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content |
| WO2022150735A1 (en) | 2021-01-11 | 2022-07-14 | Eli Lilly And Company | Anti-n3pglu amyloid beta antibodies and uses thereof |
| TW202300518A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-n3pglu amyloid beta antibodies and uses thereof |
| TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
| AU2022371475A1 (en) | 2021-10-22 | 2024-05-09 | Eli Lilly And Company | O-glcnacase (oga) inhibitor combination therapy |
| AU2022376930A1 (en) | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| TW202336034A (en) | 2021-10-29 | 2023-09-16 | 美商美國禮來大藥廠 | Compounds and methods targeting interleukin-34 |
| CA3236504A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| CA3236547A1 (en) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Compounds and methods targeting interleukin-34 |
| WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
| WO2024020470A1 (en) | 2022-07-21 | 2024-01-25 | Eli Lilly And Company | PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| JP2006513259A (en) | 2002-07-24 | 2006-04-20 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Prevention, treatment and diagnosis of diseases associated with beta-amyloid production and / or aggregation |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| SI1720909T1 (en) * | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta antibody |
| SG190665A1 (en) * | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| CA2657681C (en) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Humanized antibodies against beta amyloid protein |
| AU2008242648B2 (en) * | 2007-04-18 | 2013-09-12 | Janssen Alzheimer Immunotherapy | Prevention and treatment of cerebral amyloid angiopathy |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| JP2011527338A (en) | 2008-07-09 | 2011-10-27 | ユニバーシティー オブ チューリッヒ | How to promote neurogenesis |
| CN102131519B (en) | 2008-07-21 | 2016-01-13 | 前体生物药物股份公司 | diagnostic antibody assay |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| PL3042917T3 (en) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
-
2011
- 2011-08-09 PL PL15196358T patent/PL3042917T3/en unknown
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/en unknown
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/en active IP Right Grant
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/en active Active
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 PL PL11745672T patent/PL2603523T3/en unknown
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/en active Active
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 PL PL18150424T patent/PL3339323T3/en unknown
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/en active Active
- 2011-08-09 MA MA35653A patent/MA34461B1/en unknown
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 RS RS20191581A patent/RS59652B1/en unknown
- 2011-08-09 RS RS20180323A patent/RS57026B1/en unknown
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/en unknown
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/en active IP Right Grant
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/en active
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 ES ES18150424T patent/ES2764728T3/en active Active
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/en unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/en unknown
- 2011-08-09 EA EA201270813A patent/EA023021B1/en not_active IP Right Cessation
- 2011-08-09 SI SI201131817T patent/SI3339323T1/en unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/en unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/en unknown
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/en active Active
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/en active Active
- 2011-08-09 PT PT181504242T patent/PT3339323T/en unknown
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/en unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/en active IP Right Grant
- 2011-08-09 MX MX2013001716A patent/MX342782B/en active IP Right Grant
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/en unknown
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-09-08 UA UAA201301508A patent/UA107600C2/en unknown
-
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
-
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/en unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/en unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/en unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/en unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/en unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/en unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/en unknown
- 2013-07-11 HK HK13108135.4A patent/HK1180703A1/en unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
-
2016
- 2016-02-10 HR HRP20160151TT patent/HRP20160151T1/en unknown
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/en active Active
-
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/en unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/en unknown
-
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/en unknown
-
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/en unknown
-
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34461B1 (en) | BETA-AMYLOID N3PGIU ANTI-PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG10201914119TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| MA44659B1 (en) | ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS | |
| MA43186B1 (en) | Antibodies specifically binding to pd-1 and uses thereof | |
| MA33213B1 (en) | ANTAGONIST ANTIBODY SPECIFIC TO A HETERODIMERE ALPHA-4-BETA-7 | |
| GEP20227369B (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MA40476B1 (en) | Antibodies and anti-lag3 antigen binding fragments | |
| MA37538B1 (en) | Anti-Ly6 antibodies and immunoconjugates and methods of use | |
| MA40609B1 (en) | Cd123 binding agents and their uses | |
| MA40913A (en) | ANTIBODY-DRUG CONJUGATES | |
| MA34555B1 (en) | NOVEL ANTIGEN-BINDING PROTEINS | |
| MA37619A1 (en) | Anti-fcrn antibodies | |
| MA33757B1 (en) | HUMAN IL-23 ANTIGEN BINDING PROTEINS | |
| MA33208B1 (en) | ANTI-FGFR3 ANTIBODIES AND METHODS OF USE THEREOF | |
| UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| MA30384B1 (en) | COMBINATORIAL THERAPIES | |
| EA201171388A1 (en) | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF BETA AMYLOID PEPTIDE | |
| MA32190B1 (en) | Antibodies to angiopoietin 1 and angiopoietin 2 and their use | |
| MA33256B1 (en) | Antibody ,,, fcrh5 and methods of use | |
| MA34818B1 (en) | ANTI-PCSK9 ANTIBODIES AND METHODS OF USE | |
| MA34647B1 (en) | METHODS OF TREATING POLYARTHRITERHUMATOID USING DIL-17 ANTAGONISTS | |
| UA106194C2 (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
| BR112016018205A2 (en) | Alzheimer's treatment methods | |
| MA29369B1 (en) | FIXED ASSAY OF ANTI-HER ANTIBODIES | |
| IN2014KN02933A (en) |